Compare Ishares Msci Brazil ETF (EWZ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Ishares Msci Brazil ETF trades at $34.11, while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| EWZ | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $41.75 | $529.65 |
52-Week Low | $27.36 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
